Jeremy Webster > Mewburn Ellis LLP > Manchester, England > Lawyer Profile

Mewburn Ellis LLP
M1 3LD

Work Department

Head of Chemistry


Partner, Patent Attorney, Chemistry


Jeremy has over 15 years’ experience in chemistry and materials science patents, with a focus on polymers, composites and advanced materials, as well as consumer products. He has an enviable success rate with opposition and appeals and regularly represents clients at oral proceedings before the EPO. He provides early input to help ensure that appropriate and persuasive data is presented and works with a wide range of clients on invention capture and filing strategy, as well as driving efficiency and adding value in strategic portfolio management. Jeremy heads up the firm’s Chemistry practice group and is a member of our Management Board.

Jeremy’s clients include Japan-based multinational chemical and materials companies, large consumer goods businesses and universities.


Jeremy has a degree and PhD in chemistry from the University of Nottingham. He qualified as a Chartered Patent Attorney and European Patent Attorney in 2005.

Lawyer Rankings

London > TMT (technology, media and telecoms) > PATMA: Patent attorneys

With offices in London, Bristol, Manchester, Cambridge and Munich, Mewburn Ellis LLP is well-placed to offer a seamless European service to its roster of clients and handles both the filing and prosecution of UK and German patent applications, as well as managing global IP portfolios for multinational companies. In Manchester, Jeremy Webster heads up the chemistry practice, which focuses on the full range of chemical innovations, as well as advanced material materials, such as graphene and battery technologies, and polymers. The engineering and ICT team, which is led by Manchester-based Graeme Moore and houses both patent attorneys and design specialists, has demonstrable experience in software, bioinformatics and quantum computing mandates. From the firm’s Bristol office, Simon Kiddle spearheads the life sciences practice. The team advises on patents in biologics, bioinformatics, cell therapies, vaccines, precision medicines and future food. The firm has recently seen an uptick in contentious matters, demonstrating a strong track record in high-value oppositions at the EPO. In a notable appointment, biopharma specialist Robert Andrews recently became the firm’s first chief inclusion and diversity officer.